Compare SMG & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMG | IOVA |
|---|---|---|
| Founded | 1868 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 1.5B |
| IPO Year | 2012 | 2008 |
| Metric | SMG | IOVA |
|---|---|---|
| Price | $64.69 | $3.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $73.00 | $9.00 |
| AVG Volume (30 Days) | 908.3K | ★ 12.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ 504.92 | 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,016,500,000.00 | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | $2.63 | $40.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $45.61 | $1.64 |
| 52 Week High | $72.35 | $5.63 |
| Indicator | SMG | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 50.65 |
| Support Level | $58.74 | $2.02 |
| Resistance Level | $65.38 | $4.33 |
| Average True Range (ATR) | 2.74 | 0.29 |
| MACD | 0.47 | 0.02 |
| Stochastic Oscillator | 64.01 | 46.37 |
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.